David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Bioethics 26 (3):143-148 (2012)
While medicine may agree in principle that cancer screening requires informed consent, such consent is not, in fact, common practice. In the case of prostate-cancer screening this means that men in large numbers undergo PSA testing with little understanding of its liabilities – in particular, that it may or may not decrease mortality, often detects cancer of questionable significance, and may lead to unnecessary surgery. Given that prostate cancer is known to be overtreated and that family history is a risk factor, it follows that a man diagnosed with prostate cancer, even if it is of no clinical significance, automatically promotes his son into the high-risk category; and given that those so categorized are subject to heightened medical surveillance and that the more diligently medicine searches for prostate cancer the more likely it is to find it, it follows that the sons of men diagnosed as a result of PSA testing are at risk of being overdiagnosed (and overtreated) precisely because their father was. Twenty years into the PSA revolution, its generational consequences have not been discussed in the medical literature
|Keywords||harm prevention informed consent|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
R. G. Jepson (2005). How Should We Measure Informed Choice? The Case of Cancer Screening. Journal of Medical Ethics 31 (4):192-196.
Susan Gilbert (2010). Personalized Cancer Care in an Age of Anxiety. Hastings Center Report 40 (5):18-21.
Stewart Justman (2011). Forfeited Health: Response to Open Peer Commentaries on “What's Wrong With Chemoprevention of Prostate Cancer?”. American Journal of Bioethics 11 (12):W1-W2.
P. Vineis & R. Satolli (2012). From Figures to Values: The Implicit Ethical Judgements in Our Measures of Health. Public Health Ethics 5 (1):22-28.
Mary McNaughton Collins, Floyd J. Fowler, Richard G. Roberts, Joseph E. Oesterling, George J. Annas & Michael J. Barry (1997). Medical Malpractice Implications of PSA Testing for Early Detection of Prostate Cancer. Journal of Law, Medicine and Ethics 25 (4):234-242.
Leslie E. Blumenson (1987). How Would a Latent Period for Early Breast Cancer Affect the Benefit of Screening? Theoretical Medicine and Bioethics 2 (2):169-182.
Ronald Ennis & Alan Jotkowitz (2011). Good Ethics Begins With Sound Medicine: Prostate Cancer Screening and Chemoprevention. American Journal of Bioethics 11 (12):26-27.
Rebecca Dresser (2011). Bioethics and Cancer: When the Professional Becomes Personal. Hastings Center Report 41 (6):14-18.
Stewart Justman (2011). What's Wrong With Chemoprevention of Prostate Cancer? American Journal of Bioethics 11 (12):21-25.
Added to index2010-05-18
Total downloads13 ( #125,816 of 1,100,097 )
Recent downloads (6 months)4 ( #90,386 of 1,100,097 )
How can I increase my downloads?